Thin
High-Quality Tirzepatide CAS NO: 2023788-19-2 Manufacturer, Quotes for Ghana Formulation
High-Quality Tirzepatide CAS NO: 2023788-19-2 Manufacturer, Quotes
Direct supply of high-purity lyophilized therapeutic peptide active pharmaceutical ingredients (APIs), engineered for stability in tropical climates and backed by complete technical release documentation.
Analyzing epidemiological shifts, regulatory clearance pathways through the Ghana FDA, cold-chain distribution across Greater Accra and Ashanti, and systemic supply solutions.
Ghana is confronting a sharp rise in adult Type 2 Diabetes Mellitus (T2DM) and comorbid obesity, notably concentrated around metropolitan zones like Accra, Kumasi, and Sekondi-Takoradi. Traditional oral secretagogues and basic insulins frequently fail to achieve glycemic targets without hypoglycemia, making long-acting GLP-1 receptor agonists clinically essential for cardiovascular and metabolic outcome protection.
Importation and commercial handling of peptide active pharmaceutical ingredients require stringent documentation under Ghana Food and Drugs Authority (FDA) Part 7 (Public Health Act, 2012, Act 851). Our peptide lots arrive fully fortified with comprehensive CTD-ready dossiers, including Certificate of Analysis (CoA), EDQM/USP-aligned impurity profiling, and residual solvent clearances conforming to ICH Q3C standards.
Ghana's tropical climate (Zone IVb conditions: 30°C / 75% RH) poses acute destabilization risks to synthetic peptides susceptible to deamidation and oxidation. We utilize advanced lyophilization freeze-drying cycles creating ultra-pure, moisture-depleted cakes protected under vacuum-sealed nitrogen, maintaining peak bio-identity through transit into Kotoka International Airport (ACC).
Synthesizing complex multi-branched glucagon-like peptide-1 analogues such as Semaglutide (31-mer backbone with an AEEA-AEEA-γ-Glu-C18 diacid side-chain at Lys26) or Tirzepatide (39-mer with dual GIP/GLP-1 activation) requires world-class organic synthesis infrastructure. Our Hangzhou chemical synthesis headquarters harnesses hybrid Solid-Phase (SPPS) and Liquid-Phase Peptide Synthesis (LPPS).
By utilizing low-racemization condensing reagents, automated multi-vessel reactors up to 5,000L, and precision axial compression preparative chromatography columns, we eliminate deletion sequences, beta-elimination impurities, and diastereomers that degrade active peptide potency.
Every batch dispatched to Ghanaian research facilities, hospitals, or private labelers is tested across mandatory quality thresholds:
Transparent benchmark wholesale tiers for laboratory research, formulation scale-up, and institutional supply lines. Prices in USD with duty-paid and air courier transit options to Accra.
| Peptide Molecule | CAS Number | Target Receptor | Standard Purity | Reference MOQ | Indicative Price Range (USD/g) | Supply Status (Ghana) |
|---|---|---|---|---|---|---|
| Semaglutide API | 910463-68-2 | GLP-1R Selective | ≥ 99.0% (HPLC) | 10g / 100g | $140 - $260 / g | In Stock · Ready Air Cargo |
| Tirzepatide API | 2023788-19-2 | Dual GLP-1 / GIP | ≥ 99.2% (HPLC) | 10g / 100g | $160 - $290 / g | In Stock · High Demand |
| Retatrutide API | 2381089-83-2 | Triple GLP-1 / GIP / GCGR | ≥ 99.0% (HPLC) | 10g / 50g | $220 - $380 / g | Pilot Batches Ready |
| Dulaglutide Intermediates | 923950-08-7 | GLP-1-Fc Conjugate | ≥ 98.5% (HPLC) | 25g / 100g | Inquire per volume | Custom Campaign |
| Tesamorelin Acetate | 218949-48-5 | GHRH Analog (Visceral Fat) | ≥ 98.5% (HPLC) | 10g / 100g | $110 - $190 / g | In Stock · Fast Courier |
| Eptifibatide Bulk | 188627-80-7 | GPIIb/IIIa Antagonist | ≥ 99.0% (HPLC) | 50g / 500g | $75 - $130 / g | Commercial Continuity |
| Vasopressin Synthetic | 50-57-7 | V1a / V2 Receptors | ≥ 98.5% (HPLC) | 10g / 100g | $65 - $115 / g | Immediate Dispatch |
*Note: Tiers fluctuate according to order volume, counter-ion specification (Acetate vs. TFA salt), and target custom packaging. Contact commercial desk for tailored project proformas.
How healthcare institutions and pharmaceutical pioneers in West Africa leverage custom peptide development across clinical, compounding, and next-generation delivery formats.
Ghana's industrial vision involves domestic value-added pharmaceutical manufacturing. Importers and hospital manufacturing units utilize our sterile, endotoxin-tested peptide lyophilizates to formulate multi-dose prefilled pens or clinical vials under cleanroom ISO Class 5 conditions, reducing reliance on expensive finished branded imports that strain foreign exchange reserves.
Academic and clinical research hubs, including teams collaborating with Korle-Bu Teaching Hospital and KNUST, require highly reproducible reference standards and raw incretin materials. Our batch-to-batch consistency allows precise pharmacodynamic and pharmacokinetic evaluation in cohorts under investigation for metabolic syndrome, NAFLD/MASH, and cardiovascular risk reduction.
The global peptide horizon is advancing rapidly from single GLP-1 receptor activation toward dual (GLP-1/GIP) and triple (GLP-1/GIP/Glucagon - Retatrutide) agonists, inducing profound weight reductions exceeding 24% in clinical datasets. Furthermore, technologies involving SNAC-based oral delivery co-formulations are under active feasibility mapping for emerging markets with limited cold-chain infrastructure.
When selecting a chemical peptide partner, procurement managers must move beyond quoted price-per-gram to verify complete chemical, microbial, and regulatory robustness.
During solid-phase cleaving, trifluoroacetic acid (TFA) forms salts with basic peptide residues. For human injection formulation, excessive TFA induces local tissue toxicity. Insist on acetate counter-ion conversion with analytical verification (≤ 0.2% residual TFA).
Review reverse-phase HPLC chromatograms at multiple wavelengths (214nm, 254nm, 280nm). Ensure no single unspecified impurity exceeds 0.5%, and total diastereomeric impurities are characterized through high-resolution LC-MS.
Verify that the cake structure is uniform, white to off-white, with low residual water (≤ 5.0%). Moisture accelerates aggregation and peptide deamidation, critically destroying bioactivity under West African ambient conditions.
Explore our comprehensive portfolio of generic peptide APIs, immune support polypeptides, and metabolic regulators synthesized under strict cGMP protocols.
Expert answers addressing minimum order volumes, customs clearance at Kotoka Airport, cold-chain transport packaging, and regulatory documentation support.
Standard air shipments dispatch via validated international cold-chain carriers (DHL Medical Express, FedEx Priority) reaching Kotoka International Airport (ACC) within 4 to 7 business days. Lyophilized peptides are packaged with phase-change cold packs or dry ice inside insulated EPS/VIP thermal containers to maintain 2°C–8°C throughout transit.
Yes. We furnish complete regulatory dossiers according to CTD specifications, including detailed raw material sourcing, synthesis route validation, batch Certificates of Analysis (CoA) with HPLC and MS spectra, heavy metals analysis, residual solvent declarations, and Zone IVb stability testing data.
For academic research and pre-formulation feasibility in Ghana, our catalog MOQ begins at 10 grams. For commercial compounding facilities and institutional distributors, we supply validated batch sizes of 100g, 500g, 1kg, and custom multi-kilogram commercial contracts.
Standard research peptides are commonly provided in trifluoroacetic acid (TFA) salt form. However, for therapeutic use, human clinical trials, or downstream injectable compounding in Ghana, we offer customized ion exchange producing high-purity Acetate or Hydrochloride salts with ultra-low residual TFA (< 0.2%).
Speak directly with our pharmaceutical synthesis engineers and West Africa export directors to receive customized proforma invoices, volume batch discounts, and technical dossiers.